Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research

Related Links:

Bargou Andreas Rosenwald Thorsten Stühmer Ellen Leich Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRASp.G12C entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, incl...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Giavaresi Alessandro Osteolytic bone disease is the major complication associated with the progression of multiple myeloma (MM). Recently, extracellular vesicles (EVs) have emerged as mediators of MM-associated bone disease by inhibiting the osteogenic differentiation of human mesenchymal stem cells (hMSCs). Here, we investigated a correlation between the EV-mediated osteogenic inhibition and MM vesicle content, focusing on miRNAs. By the use of a MicroRNA Card, we identified a pool of miRNAs, highly expressed in EVs, from MM cell line (MM1.S EVs), expression of which was confirmed in EVs from bone marrow (BM) p...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionOur results demonstrate that Egyptian children diagnosed with JMML have high frequency of NRAS/KRAS mutations and lower frequency of PTPN11 mutations as compared to previous studies. The concept of mutually exclusive RAS pathway mutations was clearly observed in our patients. All cancer centers in our region should start implementing molecular diagnostics methods before confirming the diagnosis of JMML and before offering HSCT.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Bone is one of the most common sites of metastases, particularly for breast, lung, prostate cancer, and multiple myeloma [1]. The most typical anatomical regions of bone metastases are the spine, the proximal femur, and the humerus [2]. Particularly for proximal femur lesions, 50% occur in the femoral neck, 30% occur in the subtrochanteric region, and 20% occur in the intertrochanteric region [3]. While current advances in oncology have improved the mean overall survival of patients with metastatic musculoskeletal disease, bone metastases cause significant morbidity, including pain, limitations in daily activities, and pat...
Source: Injury - Category: Orthopaedics Authors: Source Type: research
Juvenile Myelomonocytic Leukemia (JMML) is a rare hematological malignancy. Developing countries are lagging behind in their facilities in molecular diagnostics. The bone marrow for 41 Egyptian children treated as JMML were retrospectively studied for RAS mutations. Mutations were detected in 80% of patients. Cancer centers in our region should start implementing molecular diagnostics before confirming the diagnosis of JMML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Sara Palchetti Angela Santoni Cinzia Fionda Bone marrow stromal cells (BMSCs) strongly contribute to multiple myeloma (MM) progression, promoting the survival and growth of malignant plasma cells (PCs). However, the possible impact of these cells on the immune-mediated recognition of MM cells remains largely unknown. DNAM-1 activating receptor plays a prominent role in NK cell anti-MM response engaging the ligands poliovirus receptor (PVR) and nectin-2 on malignant PCs. Here, we analysed the role of MM patient-derived BMSCs in the regulation of PVR expression. We found that BMSCs enhance PVR surface expression on ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Blood Cancer Journal, Published online: 13 February 2020; doi:10.1038/s41408-020-0273-xDevelopments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
l Çiçek Black cohosh is a well-established medicinal plant and preparations of its rootstock are used for the treatment of mild climacteric complaints. The compounds considered responsible for the therapeutic effect are triterpene glycosides, characterized by a cycloartane scaffold and a pentose moiety. Because some of these triterpenoids were found to exhibit relevant cytotoxic effects against human breast cancer cells, we decided to investigate their activity on multiple myeloma cell lines NCI-H929, OPM-2, and U266. In a systematic approach, we initially tested three known cytotoxic compounds of thre...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “Wh...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
es Vasconcelos Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors and monoclonal antibodies. Survival outcomes have improved substantially due to the introduction of many of these drugs allied with their rational use. Nonetheless, MM patients successively relapse after one or more treatment regimens or become refractory, mostly due to drug resistance. This review focuses on the main drugs used in MM treatment and on causes of drug resistance, including...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Dexamethasone | Myeloma | Velcade | Vitamin C